Abstract

▼ Sacubitril valsartan (Entresto—Novartis) is a new oral drug licensed for the treatment of symptomatic chronic heart failure in adults with reduced ejection fraction.¹ It is described as an angiotensin receptor neprilysin inhibitor and contains the neprilysin inhibitor, sacubitril and the angiotensin II receptor antagonist, valsartan.^1-3 Here, we review the evidence for sacubitril valsartan and consider its place in the management of heart failure.